Skip to main content

Table 1 General characteristics of 31 patients

From: Clinical application of computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases

Patient no. Age Gender Location of primary tumor TNM classification Site of metastases Pre-procedural NRS Post-procedural NRS (6 months) Size of lymph node metastasis (cm*cm) Pre-treatments
1 59 M NPC IVT3N3M1 L 8 3 8*5 Cisplatin + fluorouracil (4), radiotherapy (2)
2 63 M NPC IVT1N1M1 L 7 2 3*3 Cisplatin + fluorouracil (4)
3 65 F NPC IVT2N3M1 L 7 2 6*3 Cisplatin + fluorouracil (4)
4 60 M NPC IVT2N2M1 L 7 2 4*3 Cisplatin + fluorouracil (4), radiotherapy (2), surgery (2)
5 55 F NPC IVT3N3M1 R 9 2 7*4  
6 61 M NPC IVT2N1M1 R 9 3 5*2 Cisplatin + fluorouracil (3)
7 63 F NPC IVT2N1M1 L 8 3 5*4 Cisplatin + fluorouracil (3)
8 54 F NPC IVT1N3M1 R 7 3 6*3 Radiotherapy (2)
9 52 M NPC IVT4N3M1 L 9 2 8*5 Cisplatin + fluorouracil (4) surgery (2)
10 70 M Tongue cancer IVT1N2M1 R 8 2 3*3  
11 65 M Tongue cancer IVT2N3M1 L 7 3 5*3 Cisplatin vincristine methotrexate (3)
12 72 F Tongue cancer IVT2N2M1 L 8 2 5*4  
13 68 M Tongue cancer IVT2N3M1 R 6 2 4*4 Cisplatin vincristine methotrexate (3)
14 74 M Tongue cancer IVT2N3M1 L 8 2 5*4 Radiotherapy (2)
15 71 F Tongue cancer IVT2N3M1 R 7 1 4*3  
16 69 F Tongue cancer IVT2N3M1 R 7 2 4*4 Cisplatin vincristine methotrexate (3)
17 67 F Tongue cancer IVT3N3M1 L 9 3 6*7 Cisplatin vincristine methotrexate (3)
18 75 M Laryngocarcinoma IVT2N3M1 R 9 2 5*4 Surgery (2)
19 69 M Laryngocarcinoma IVT3N2M1 R 8 3 7*4  
20 70 M Laryngocarcinoma IVT2N3M1 R 9 2 5*3 Radiotherapy (2)
21 73 M Laryngocarcinoma IVT2N3M1 R 8 2 6*5  
22 70 F Laryngocarcinoma IVT2N2M1 R 9 2 4*4 Surgery (2)
23 75 M Maxillary sinus carcinoma IVT2N3M1 R 8 2 6*4 Carboplatin (4)
24 70 M Maxillary sinus carcinoma IVT2N2M1 R 7 2 5*4 Cisplatin (3)
25 51 F Maxillary sinus carcinoma IVT2N3M1 L 6 2 6*4 Cisplatin (3)
26 75 F Thyroid cancer IVT2N1M1 R 7 8 6*5 Radiotherapy (2)
27 57 M Thyroid cancer IVT2N1M1 L 8 2 5*5  
28 61 M Thyroid cancer IVT3N1M1 R 9 2 5*3  
29 59 F Thyroid cancer IVT2N1M1 L 7 2 4*4 Surgery (2)
30 48 M Thyroid cancer IVT3N1M1 L 7 2 5*4  
31 74 M Thyroid cancer IVT2N1M1 L 8 2 6*5 Surgery (2)
  1. M male, F female, L left cervical lymph node, R right cervical lymph node, NPC nasal pharyngeal cancer
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us